Evidence map›Paper›PMID 41177875›Full record

ArticleEuropean journal of medical research2025

An innovative approach for predicting prostate cancer Gleason grading: machine learning-based fusion of multimodal ultrasound, clinical and laboratory indicators.

WenLong Xie, GuangZhen Wu, XiaoChen Qi, Lin Zhong, LiYing Guo, MengYing Tong, Ying Che

Abstract read
In one paragraph

Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

WenLong XieDepartment of Ultrasound, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
GuangZhen WuDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
XiaoChen QiDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Lin ZhongDepartment of Pathology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
LiYing GuoDepartment of Ultrasound, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
MengYing TongDepartment of Ultrasound, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Ying CheDepartment of Ultrasound, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China. medxwl0119@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer is a common malignancy among elderly males with a growing incidence. While prostate biopsy remains the gold standard for diagnosis, this invasive procedure is poorly tolerated by some patients. The Gleason grade group (GGG) plays a critical role in predicting metastatic risk, guiding treatment selection, and is strongly associated with survival outcomes. Consequently, noninvasive prediction of prostate cancer Gleason grading has emerged as a research priority. This study aimed to develop a noninvasive predictive model integrating multimodal ultrasound data and clinical laboratory biomarkers to preoperatively determine GGGs in prostate cancer patients.

methodsThis single-center study enrolled 329 prostate cancer patients meeting predefined inclusion criteria. All participants underwent prostate biopsy with subsequent Gleason grading and were categorized into three groups: low-grade (Gleason score ≤ 6), intermediate-grade (Gleason score 7), and high-grade (Gleason score ≥ 8). Thirty-seven predictive parameters were collected, including clinical laboratory biomarkers, systemic inflammatory markers (e.g., neutrophil-to-lymphocyte ratio), and multimodal ultrasound data: Grayscale sonographic characteristics, contrast-enhanced ultrasound (CEUS) parameters, elastography parameters, and radiofrequency signal data. Following feature selection, five clinically significant predictors were identified. Multiple machine learning algorithms were implemented for predictive modeling, and model performance was quantified using accuracy, recall, and F1-score.

resultsSix machine learning-based predictive models were developed and evaluated. The Decision Tree model achieved an accuracy of 0.818, recall of 0.818, and F1-score of 0.816. The Random Forest classifier demonstrated an accuracy of 0.820, recall of 0.820, and F1-score of 0.820. The K-Nearest Neighbors algorithm yielded an accuracy of 0.788, recall of 0.788, and F1-score of 0.801. The Gradient Boosting Decision Tree (GBDT) model exhibited superior predictive capability with an accuracy of 0.848, recall of 0.848, and F1-score of 0.849. The XGBoost algorithm had an accuracy of 0.818, recall of 0.789, and F1-score of 0.796, while the Naive Bayes classifier attained an accuracy of 0.773, recall of 0.773, and F1-score of 0.779. Comparative analysis revealed that the GBDT model demonstrated optimal performance among the evaluated algorithms, suggesting its potential clinical significance in predicting Gleason grades.

conclusionUltrasonography, being noninvasive, radiation-free, and cost-effective, demonstrates high clinical feasibility for implementation in routine practice. The predictive model established through multimodal ultrasound parameters effectively predicts the Gleason grade of prostate cancer.

Indexed as

Machine LearningProstatic NeoplasmsAgedBiomarkers, TumorHumansMaleMiddle AgedNeoplasm GradingUltrasonographyBiomarkers, TumorGleason gradingInflammatory biomarkersMachine learningPredictive modelProstate cancerUltrasonography

Identifiers

PMID41177875
PMCPMC12581374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.